Divis Laboratories Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/eygejecyquzbe1pjsv9v33fa.pdf

Key Takeaways


The Margin Story: Cost Structure Is Improving Faster Than Guidance Admits

Nilima Prasad Divi: "Now, why is it 32% from 40%? I think multiple reasons. One, yes, the CS is slightly higher than what it used to be. But also you need to realize we went into backward integration heavily in the Unit 3 Kakinada plant. And over there, we would say we are trying to make sure our supply chain is protected. Along with that, we do see certain cost benefits even over there."

The Three Big Projects: Commercialization Is Now Close

Dr. Kiran S. Divi: "Till now, we did not receive any notice on either of them. But as the validation batches go to our customers and they qualify us, then they submit the batches, it is then that we would know whether they would need an inspection or if they would clear the file based on previous history."

Peptides: A Top-Three Ambition, Light on Proof Points

Dr. Kiran S. Divi: "If I say that, it will put me in trouble because I have NDA in place. All I will say is, with the futuristic capacity, we will be in the top three players."

Cash Flow & Working Capital: The Capex Cycle Is Consuming Cash


Demand & Growth: Broad-Based, with Custom Synthesis Leading

Dr. Kiran S. Divi: "See, peptide itself is a very complex chemistry. Manufacturing itself requires a lot of know-how and a lot of automation, a lot of technology. The whole synthesis and the process, either it is fragments or it is a finished product all the way downstream, and then you are talking about API, everything has its own challenge."

Guidance & Commitments

CommitmentSpecificsTimeline
First dedicated project commercializationOne of three major dedicated investment projects is very close to commercializationImminent (no date given)
Remaining two dedicated projectsExpected to see commercialization factor come inNext one to two quarters
H2 FY27 revenue growthDouble-digit growthH2 FY27
Full-year capex~₹2,000 crores, plus or minus 20%FY27
Medium-term capex run rate₹2,000 crores plus or minus 20% year on year, based on increasing RFPs and customer interestNext two to three years
EBITDA margin32–35% (guidance held despite H1 at ~40%)FY27
Peptide global positionTop three players globally with futuristic capacityNo date (capacity being installed)

Key Metrics

MetricQ2 FY27
Consolidated total income₹3,770 cr, +32% YoY from ₹2,860 cr
Profit before tax₹1,505 cr, +65% YoY from ₹912 cr
Profit after tax₹1,127 cr, +64% YoY from ₹689 cr
H1 FY27 consolidated total income₹6,907 cr, vs ₹5,389 cr in H1 FY26
H1 FY27 profit after tax₹2,029 cr, +64% YoY from ₹1,234 cr
H1 FY27 constant currency revenue growth17% YoY
H1 FY27 revenue mix: generics / custom synthesis38% generics, 62% custom synthesis
H1 FY27 nutraceutical revenue₹571 cr, vs ₹492 cr in H1 FY26
H1 FY27 net material consumption~32% of sales revenue, vs 40% in H1 FY26
H1 FY27 net forex gain₹20 cr, vs gain of ₹103 cr in H1 FY26
Assets capitalized in Q2 FY27₹772 cr; H1 FY27 total: ₹1,223 cr
Capital work in progress₹1,638 cr as of Sep 30, 2026
Cash balances₹2,181 cr as of Sep 30, 2026
Trade receivables₹3,705 cr as of Sep 30, 2026
Inventories₹5,325 cr as of Sep 30, 2026
H1 FY27 cash flow from operations (pre-tax)₹959 cr, declined 50% YoY
Overall asset turnover~1.5x
H1 FY27 finished goods and work-in-progress build-up₹1,197 cr
CDMO business YoY growth~50% in Q2 FY27, similar to Q1 FY27 growth in the 40s (per an analyst's math)
Annual capex outlook~₹2,000 cr, plus or minus 20%, for the next few years
CSR: daily access to clean drinking water>13 lakh individuals